Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.77 USD -1.53%
Market Cap: 146B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pfizer Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Other Non-Cash Items
$6.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
35%
Johnson & Johnson
NYSE:JNJ
Other Non-Cash Items
$3.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Other Non-Cash Items
$14.3B
CAGR 3-Years
6%
CAGR 5-Years
90%
CAGR 10-Years
80%
Merck & Co Inc
NYSE:MRK
Other Non-Cash Items
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
27%
Zoetis Inc
NYSE:ZTS
Other Non-Cash Items
$242m
CAGR 3-Years
6%
CAGR 5-Years
29%
CAGR 10-Years
23%
Eli Lilly and Co
NYSE:LLY
Other Non-Cash Items
$4.5B
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
26%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
146B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.41 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Other Non-Cash Items?
Other Non-Cash Items
6.7B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Other Non-Cash Items amounts to 6.7B USD.

What is Pfizer Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
35%

Over the last year, the Other Non-Cash Items growth was 39%.

Back to Top